196 related articles for article (PubMed ID: 28068876)
1. Tissue-Engineered Model of Human Osteolytic Bone Tumor.
Villasante A; Marturano-Kruik A; Robinson ST; Liu Z; Guo XE; Vunjak-Novakovic G
Tissue Eng Part C Methods; 2017 Feb; 23(2):98-107. PubMed ID: 28068876
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
Odri G; Kim PP; Lamoureux F; Charrier C; Battaglia S; Amiaud J; Heymann D; Gouin F; Redini F
BMC Cancer; 2014 Mar; 14():169. PubMed ID: 24612486
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.
Zhou Z; Guan H; Duan X; Kleinerman ES
Cancer; 2005 Oct; 104(8):1713-20. PubMed ID: 16121404
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
5. Bioengineered Models of Solid Human Tumors for Cancer Research.
Marturano-Kruik A; Villasante A; Vunjak-Novakovic G
Methods Mol Biol; 2016; 1502():203-11. PubMed ID: 27115504
[TBL] [Abstract][Full Text] [Related]
6. Tissue-Engineered Bone Tumor as a Reproducible Human in Vitro Model for Studies of Anticancer Drugs.
Sakolish C; House JS; Chramiec A; Liu Y; Chen Z; Halligan SP; Vunjak-Novakovic G; Rusyn I
Toxicol Sci; 2020 Jan; 173(1):65-76. PubMed ID: 31626302
[TBL] [Abstract][Full Text] [Related]
7. Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma.
Lau YS; Adamopoulos IE; Sabokbar A; Giele H; Gibbons CL; Athanasou NA
Br J Cancer; 2007 Jun; 96(11):1716-22. PubMed ID: 17533390
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Thudi NK; Martin CK; Nadella MV; Fernandez SA; Werbeck JL; Pinzone JJ; Rosol TJ
Prostate; 2008 Jul; 68(10):1116-25. PubMed ID: 18461562
[TBL] [Abstract][Full Text] [Related]
10. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
Yang C; Davis JL; Zeng R; Vora P; Su X; Collins LI; Vangveravong S; Mach RH; Piwnica-Worms D; Weilbaecher KN; Faccio R; Novack DV
Cancer Discov; 2013 Feb; 3(2):212-23. PubMed ID: 23269702
[TBL] [Abstract][Full Text] [Related]
12. Ewing sarcoma cells express RANKL and support osteoclastogenesis.
Taylor R; Knowles HJ; Athanasou NA
J Pathol; 2011 Oct; 225(2):195-202. PubMed ID: 21547906
[TBL] [Abstract][Full Text] [Related]
13. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
Greiner S; Kadow-Romacker A; Schmidmaier G; Wildemann B
J Biomed Mater Res A; 2009 Oct; 91(1):288-95. PubMed ID: 18980195
[TBL] [Abstract][Full Text] [Related]
14. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
15. Loss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis.
Talbot J; Brion R; Picarda G; Amiaud J; Chesneau J; Bougras G; Stresing V; Tirode F; Heymann D; Redini F; Verrecchia F
Biochim Biophys Acta; 2013 Apr; 1832(4):553-64. PubMed ID: 23313578
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
Odri GA; Dumoucel S; Picarda G; Battaglia S; Lamoureux F; Corradini N; Rousseau J; Tirode F; Laud K; Delattre O; Gouin F; Heymann D; Redini F
Cancer Res; 2010 Oct; 70(19):7610-9. PubMed ID: 20841471
[TBL] [Abstract][Full Text] [Related]
17. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
Schindeler A; Little DG
Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
[TBL] [Abstract][Full Text] [Related]
18. Effects of two novel bisphosphonates on bone cells in vitro.
Evans CE; Braidman IP
Bone Miner; 1994 Aug; 26(2):95-107. PubMed ID: 7994190
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
[TBL] [Abstract][Full Text] [Related]
20. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
